ArticleArthritis research & therapy2026
Reassessing the role of watchful waiting strategy for IgG4-related disease: a real-world study.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Management of IgG4-Related Disease.Current rheumatology reports · 2026Review
- A Rare Case of Gastritis with Prominent IgG4-Positive Plasmacytosis Mimicking IgG4-Related Gastrointestinal Disease.Inflammatory intestinal diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTo investigate the feasibility and potential efficacy of “watchful waiting” strategy in IgG4-related disease (IgG4-RD) patients being asymptomatic or having low disease activity.
methodsIgG4-RD patients presented in our station between October 2018 to October 2022, who met the criteria for “watchful waiting” modified from the 2015 International Consensus Guidance Statement were included. Deidentified clinical laboratory data were retrospectively collected and statistically analyzed between patients undergone watchful waiting (“WAIT” group) and received routine medical treatments (“TREAT” group). Subgroup analyses in “WAIT” group were also performed to compare the features between patients with and without receiving surgical resection of involved organs.
resultsA total of 49 patients meeting the “watchful waiting” criteria were included and followed for a median of 48 [IQR 24.00, 48.00] months. The median IgG4-RD responder index (RI) of them was 2; 71.4% of them were ‘Head and Neck-Limited’ clinical phenotype, and 63.3% were single organ involved. While 25 of the 49 patients chose “watchful waiting” strategy, others received treatment of glucocorticoids and steroid-sparing agents. The WAIT group showed a significantly higher cumulative recurrence rate (42.4%, 95%CI: 0.18–0.60) than the TREAT group (8.3%, 95%CI: 0-0.19), during the follow-up periods. Further analyses into the WAIT group revealed all relapse events of them were observed in patients undergone surgical resection of involved organs, who scored significantly higher based on the 2019 ACR/EULAR classification criteria for IgG4-RD.
conclusions“Watchful waiting” strategy may not be the optimal immediate choice for patients with mild symptoms, low disease activity, and limited organ involvement, even after the surgical resection of involved organs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.